Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma

Despite advances and introduction of new therapies in the last decade, metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. The development of androgen axis-targeted therapies such as abiraterone acetate, enzalutamide and darolutamide can prolong survival in mCPRC; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Seale, Katelyn Nazaneen, Labriola, Matthew K, Jiang, Xiaoyin "Sara", Armstrong, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Reports: Learning from unexpected outcome (positive or negative)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535143/
https://www.ncbi.nlm.nih.gov/pubmed/36198431
http://dx.doi.org/10.1136/bcr-2022-251036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535143/
https://www.ncbi.nlm.nih.gov/pubmed/36198431
http://dx.doi.org/10.1136/bcr-2022-251036

Ejemplares similares